Spondylitis Association of America
    Search Our Site:       

FDA Approves REMICADE for Patients with Ankylosing Spondylitis


Centocor, Inc., maker of the TNF-a Inhibitor (a biologic medication), Remicade (Infliximab) has announced that the FDA has approved the drug for use in treating ankylosing spondylitis (AS). Remicade now joins the Wyeth Pharmaceuticals medication, Enbrel (etanercept) as the only other TNF-a Inhibitor to be approved for the treatment of AS.

Remicade is administered every 6-8 weeks by means of infusion.

The drug is in the class of medication that has shown great promise in treating AS and is the only variety treatment that, according to Dr. John D. Reveille, "appears to stop the fusion" asociated with AS. But he cautions, "whether or not [the TNF-a Inhibitors] continue to work over time, remains to be seen."

The Centocor press release can be found by clicking here.

For more information on the TNF-a Inhibitors, see our ongoing special report section by clicking here.


Stay up-to-date on all the latest news and information regarding AS and related diseases with our news magazine, Spondylitis Plus. Your subscription comes free with SAA membership, so click here to join today!

        Bookmark and Share RSS Feed

About Us |  Join SAA |  Educational Materials |  Contact Us |  Privacy Statement |  Guidestar |  Good Operating Practices
© 2013 Spondylitis Association of America, All Rights Reserved